A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3362-3368

  Valero, Vicente ^a   Jones, Stephen E ^a   Von Hoff, Daniel D ^a   Booser, Daniel J ^a   Mennel, Robert G ^a   Ravdin, Peter M ^a   Holmes, Frankie A ^a   Rahman, Zia ^a   Schottstaedt, Margaret W ^a   Erban, John K ^a   Esparza Guerra, Laura ^a   Earhart, Robert H ^a   Hortobagyi, Gabriel N ^a   Burris III, Howard A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS;

EID: 0031758794     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3362     Document Type: Article

References (29)

1. Verweij J, Clavel M, Chevallier B: Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann Oncol 5:495-505, 1994
2. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
3. Lavelle F, Bissery MC, Combeau C, et al: Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22:3-16, 1995 (suppl 4)
4. Bissery MC, Nohynek G, Sanderink G-J, et al: Docetaxel (Taxotere): A review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6:339-368, 1995
5. Rowinsky E: The taxanes: Dosing and scheduling considerations. Oncology 11:7-19, 1997 (suppl)
6. Ringel I, Horwitz SB: Studies with RPR 56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991
7. Diaz JF, Andreau JM: Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry 32:2747-2755, 1993
8. Andreau JM, Diaz JF, Gil R, et al: Solution structure of microtubules induced by the side chain Taxol analogue Taxotere to 3 nm resolution. J Biol Chem 269:31785-31792, 1994
9. Riou JF, Petitgenet O, Combeau C, et al: Cellular uptake and efflux of docetaxel and paclitaxel in P388 cell line. Proc Am Assoc Cancer Res 35:2292, 1994 (abstr)
10. Keland LR, Abel G: Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30:444-450, 1992
11. Hanauske AR, Degen D, Hilsenbeck SG, et al: Effects of Taxotere and Taxol in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3:121-124, 1992
12. Riou JF, Naudin A, Lavelle F: Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187:164-170, 1992.
13. Haldar S, Basu A, Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233, 1997
14. Bissery MC, Guénard D, Guéritte-Voegelein F, et al: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991
15. Nicoletti MI, Lucchini V, D'Incalci M, et al: Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur J Cancer 30A:691-696, 1994
16. Vogel M, Hilsenbeck SG, Debenbrock H, et al: Preclinical activity of Taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: Comparison with Taxol and conventional antineoplastic agents. Eur J Cancer 29A:2009-2014, 1993
17. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by 3-hour infusion in patients with recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995
18. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new highly effective antineoplastic agent in the management of patients with anthracycline-resistant breast cancer. J Clin Oncol 13:2886-2894, 1995
19. Ravdin PM, Burris HA III, Cook G, et al: Phase II of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
20. Adachi I, Watanabe T, Takasima et al: A late phase II study of RP 569776 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73:210-216, 1996
21. Seidman AD, Hudis CA, Raptis G, et al: Paclitaxel for breast cancer: The Memorial Sloan-Kettering Cancer Center experience. Oncology 11:20-28, 1997 (suppl 2)
22. Vermorken JB, ten Bokkel Huinink WW, Mandjes IAM, et al: High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: A European Cancer Center trial. Semin Oncol 4:16-22, 1995 (suppl 8)
23. Ajani JA, Welch SR, Raber MN, et al: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147-159, 1990
24. Hayward JL, Rubens RD, Carbone PP, et al: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35:292-298,1977
25. Seidman AD, Hochhauser D, Gollub M, et al: Ninety-six hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996
26. Livingston RB, Ellis GK, Gralow JR, et al: Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15:1395-1400, 1997
27. Ravdin PM, Valero V, Nabholtz J-P, et al: Efficacy of a 5-day corticosteroid premedication in ameliorating Taxotere-induced fluid retenction. Proc Am Soc Clin Oncol 15:115, 1996 (abstr)
28. Taxotere Package Insert. Rhone-Poulenc Rorer, Collegeville, PA
29. Riva A, Fumoleau P, Roché H, et al: Efficacy and safety of different corticosteroid premedications in breast cancer patients treated with Taxotere. Proc Am Soc Clin Oncol 16:188a, 1997 (abstr)